Exclusive to HealthLytix, the polygenic hazard score (PHS) predicts your likelihood of developing disease as a function of age. PHS answers not only the question of if you are at risk based on your genetics, but when you are at risk, to further help guide screening decisions. You can now access your Alzheimer’s PHS analysis through Dash Genomics.
HealthLytix understands that risk for disease extends beyond genetics. We will soon integrate genetics with quantitative brain imaging, cognitive testing, and other medical information to provide updated, more precise risk assessments for Alzheimer’s and other diseases. For information on our future precision health offerings, Stay Updated.
HealthLytix is confident that precision health will expedite prevention and treatment of Alzheimer’s disease by enriching clinical trials and customizing therapies. One of our future goals as a company is to facilitate access to the best of these resources for our users. Currently, growing evidence suggests that some risk can be mitigated by certain lifestyle changes that can be engaged in immediately.